News
Camargo Pharmaceutical Services Names Carter Gaither Chief Financial Officer
(Cincinnati, Ohio; February 12, 2015) – Camargo Pharmaceutical Services, the most experienced global strategist in the drug development industry specializing in the 505(b)(2) approval pathway, has named Carter Gaither chief financial officer.
“Carter has been heavily involved in providing financial and operational leadership to emerging and growing companies,” said Ken Phelps, Camargo president and CEO. “He brings Wall Street fundraising experience, which will aid the creation of successful drug development business plans.”
Before joining Camargo, Gaither owned his own management group, which provided accounting, finance, human resources and information technology consulting services including business strategy to small businesses. He also served as managing director of finance and administration for Union Springs, a pharmaceutical startup, and manager of finance and administration for River Cities Capital Funds in Cincinnati.
A certified public accountant, Gaither has deep experiences building robust financial processes for rapidly growing, venture capital backed companies and has been instrumental in developing, implementing and securing investments to fulfill growth strategies.
“We look forward to putting Carter’s financial and strategic expertise to work for our clients,” Phelps added. “Our expertise in the 505(b)(2) approval pathway is in demand by developers around the world seeking to enter the U.S. market. Adding Carter to our team is one more way we are working to make it easier for our global partners to do business with us.”
About Camargo Pharmaceutical Services
Camargo Pharmaceutical Services is your full-service drug development partner specializing in the 505(b)(2) process. Before development even begins, we verify profit potential by working with your team to develop a comprehensive program and timeline complete with important milestones and cost objectives. We manage every facet of the plan throughout your development continuum, from feasibility assessments, formulation and testing the drug product, to conducting preclinical and clinical studies, to final submission. Connect with Camargo on LinkedIn, the President’s blog or visit www.camargopharma.com for more information.
###